Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Gloria M GagerBernd JilmaMax Paul WinterChristian HengstenbergIrene M LangAurel TomaFlorian PrüllerMarkus WallnerEwald KolesnikDirk von LewinskiJolanta M Siller-MatulaPublished in: European journal of clinical investigation (2020)
In the setting of ACS, treatment with ticagrelor or prasugrel reduced long-term mortality and 1-year MACE as compared to clopidogrel.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- antiplatelet therapy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- end stage renal disease
- coronary artery disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- type diabetes
- atrial fibrillation
- risk factors
- cardiovascular disease
- combination therapy
- patient reported